Participants of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) continue to write descriptive articles that omit the information on the dose of the drug used.1 This is especially important in the case of renal disease, for which the issue of the effectiveness of an angiotensin-converting enzyme inhibitor is addressed. The study design allowed the use of as little as 10 mg of lisinopril, which is too low a dose for efficacy. Many readers would like to know whether 3% of the patients were receiving 10 mg of lisinopril or 30% or more than half. Did the dose influence the outcome? We will have to reserve judgment on the meaning of the data until that information is available.
Hollenberg NK. Omission of Drug Dose Information. Arch Intern Med. 2006;166(3):368-369. doi:10.1001/archinte.166.3.368-b